Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus

Surgery (United States)

Volumn 153, Issue 3, 2013, Pages 333-343

  Blackham, Aaron U ^a   Northrup, Scott A ^a   Willingham, Mark ^a   D'Agostino Jr , Ralph B ^a   Lyles, Douglas S ^a   Stewart, John H ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BETA INTERFERON; INTERFERON; M PROTEIN;

ARTICLE; CANCER CELL CULTURE; CANCER SUSCEPTIBILITY; CELL VIABILITY; CONTROLLED STUDY; ELECTROPHORESIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROGENY; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; STOMATITIS; TUMOR GROWTH; TUMOR XENOGRAFT; VESICULAR STOMATITIS VIRUS; VIROGENESIS; VIRUS CELL INTERACTION; VIRUS REPLICATION;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; INTERFERON-BETA; MELANOMA; MICE; MICE, NUDE; MUTATION; ONCOLYTIC VIROTHERAPY; VESICULAR STOMATITIS INDIANA VIRUS; VIRAL MATRIX PROTEINS; VIRAL PROTEINS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84873992448     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2012.09.003     Document Type: Article

References (22)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. M.R. Middleton, J.J. Grob, N. Aaronson, G. Fierlbeck, W. Tilgen, and S. Seiter Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma J Clin Oncol 18 2000 158 166 (Pubitemid 30036349)
3. Robert C, Thomas L, Bondarenko I, O'Day S, M DJ, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.
4. P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, and J. Larkin Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2011 2507 2516
5. M.B. Atkins, M.T. Lotze, J.P. Dutcher, R.I. Fisher, G. Weiss, and K. Margolin High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 J Clin Oncol 17 1999 2105 2116 (Pubitemid 29318842)
6. D.F. Stojdl, B.D. Lichty, B.R. tenOever, J.M. Paterson, A.T. Power, and S. Knowles VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents Cancer Cell 4 2003 263 275 (Pubitemid 37329791)
7. M. Ahmed, M.O. McKenzie, S. Puckett, M. Hojnacki, L. Poliquin, and D.S. Lyles Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis J Virol 77 2003 4646 4657 (Pubitemid 36402814)
8. O. Ebert, K. Shinozaki, T.G. Huang, M.J. Savontaus, A. Garcia-Sastre, and S.L. Woo Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats Cancer Res 63 2003 3605 3611 (Pubitemid 36793042)
9. J.H. Stewart 4th, M. Ahmed, S.A. Northrup, M. Willingham, and D.S. Lyles Vesicular stomatitis virus as a treatment for colorectal cancer Cancer Gene Ther 18 2011 837 849
10. S.A. Kopecky, M.C. Willingham, and D.S. Lyles Matrix protein and another viral component contribute to induction of apoptosis in cells infected with vesicular stomatitis virus J Virol 75 2001 12169 12181 (Pubitemid 33115890)
11. M. Ahmed, S.D. Cramer, and D.S. Lyles Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses Virology 330 2004 34 49 (Pubitemid 39446565)
12. J.H. Connor, and D.S. Lyles Inhibition of host and viral translation during vesicular stomatitis virus infection. eIF2 is responsible for the inhibition of viral but not host translation J Biol Chem 280 2005 13512 13519 (Pubitemid 40517242)
13. M. Ahmed, and D.S. Lyles Identification of a consensus mutation in M protein of vesicular stomatitis virus from persistently infected cells that affects inhibition of host-directed gene expression Virology 237 1997 378 388 (Pubitemid 27489275)
14. R.M. Diaz, F. Galivo, T. Kottke, P. Wongthida, J. Qiao, and J. Thompson Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus Cancer Res 67 2007 2840 2848 (Pubitemid 46548974)
15. M. Fernandez, M. Porosnicu, D. Markovic, and G.N. Barber Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease J Virol 76 2002 895 904 (Pubitemid 34033386)
16. M. Ahmed, S. Puckett, and D.S. Lyles Susceptibility of breast cancer cells to an oncolytic matrix (M) protein mutant of vesicular stomatitis virus Cancer Gene Ther 17 2010 883 892
17. L.H. Wong, H. Sim, M. Chatterjee-Kishore, I. Hatzinisiriou, R.J. Devenish, and G. Stark Isolation and characterization of a human STAT1 gene regulatory element. Inducibility by interferon (IFN) types I and II and role of IFN regulatory factor-1 J Biol Chem 277 2002 19408 19417 (Pubitemid 34967449)
18. H.C. Steen, and A.M. Gamero The role of signal transducer and activator of transcription-2 in the interferon response J Interferon Cytokine Res 32 2012 103 110
19. L.Y. Kong, A. Gelbard, J. Wei, C. Reina-Ortiz, Y. Wang, and E.C. Yang Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model Clin Cancer Res 16 2010 2550 2561
20. A.L. Romero-Weaver, H.W. Wang, H.C. Steen, A.J. Scarzello, V.L. Hall, and F. Sheikh Resistance to IFN-alpha-induced apoptosis is linked to a loss of STAT2 Mol Cancer Res 8 2010 80 92
21. M. Porosnicu, A. Mian, and G.N. Barber The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyltransferase suicide gene Cancer Res 63 2003 8366 8376 (Pubitemid 37549491)
22. B.S. Huneycutt, Z. Bi, C.J. Aoki, and C.S. Reiss Central neuropathogenesis of vesicular stomatitis virus infection of immunodeficient mice J Virol 67 1993 6698 6706 (Pubitemid 23309138)